Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

ed at least comparable efficacy and comparable safety vs. peginterferon alfa-2a (ITT analysis), with less impairment of quality of life on treatment and fewer lost days of work. The final Phase 2b results include the following SVR rates and other findings:

Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)

-- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for

peginterferon alfa-2a administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

74.2% of those in the Albuferon 900 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a.

-- Among all treatment-adherent patients in the Albuferon 900 Q2w

treatment group, 72.3% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

treatment group reported less impairment of health-related quality of

life, compared with patients in the peginterferon alfa-2a treatment

group, as measured by both physical component and mental component SF-

36 summary measures at all time-points throughout the 48-week treatment

period.

-- Significantly fewer working patients in the Albuferon 900 Q2w treatment

group reported missing 7 days or more of work during the month prior to

their visits at Weeks 12 and 24, vs. the peginterferon alfa-2a group

(p<.05; Week 12: 4.2% for Albuferon 900 Q2w vs. 18.1% for

peginterferon alfa-2a; Week 24: 5.3% for Albuferon 900 Q2w, vs. 20.3%

for peginterferon alfa-2a).

-- The rate of discontinuations due to adverse events was 9.3% in the

Albuferon 900 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) ... previously announced acquisition of SloMedical S.R.O., a ... ranging from tubing sets to complex devices ... Flextronics provides a broad set of capabilities ... customers. Terms of the deal were not ...
(Date:12/15/2009)... -- Cumberland Pharmaceuticals Inc. ( CPIX) ... results for a patient preference study evaluating Kristalose ... laxative packaged as a crystalline powder, compared to ... the only prescription-strength laxative available in pre-measured powder ... a recent diagnosis of chronic constipation were administered ...
(Date:12/15/2009)... Dec. 15 Certified healthcare providers who ... complications from the H1N1 flu virus may now ... the Department of Health announced today. ,, ... everyone because approximately 3.2 million doses of vaccine ... it to individuals in the priority groups. ,, ...
Breaking Medicine Technology:Flextronics Completes SloMedical Acquisition 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 2Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study 3Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Upending textbook science on Alzheimers disease 61940 1Upending textbook science on Alzheimers disease 61940 2Killer fungus threatening amphibians 10867 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 1NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 10865 3
... Use of Fujirebio Diagnostics, , HE4 Test with CA125 ... Pa., Jan. 26 A pivotal clinical trial published ... Gynecologic Oncology demonstrated the utility of combining Fujirebio ... in estimating the risk of epithelial ovarian cancer in ...
... Identified, Versus MenNEW YORK, Jan. 26 Hypertrophic Cardiomyopathy ... thickening of the heart wall muscle and is the ... young adults (<40). More importantly, although heart disease ... Cardiomyopathy Association ( www.4HCM.org ) warns women remain untreated ...
Other Medicine Technology:Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 2Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 3Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass 4Cardiac Disease in Women Remains Untreated for Decades 2
(Date:12/15/2009)... 15 SUMMARY: The U.S. ... Protection and Affordable Care Act that would have ... for the safe and legal importation of lower ... by AARP and sponsored by Senators Dorgan, Snowe, ... and helped to bring down the skyrocketing costs ...
(Date:12/15/2009)... (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization ... all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders ... Description of Votes ... Votes Non-, Matter ... For Against ...
(Date:12/15/2009)... Calif., Dec. 15 Palo Alto Networks(TM), ... University has deployed its PA-4000 Series next-generation firewalls ... and for enhanced visibility and control over applications ... is a Japanese national university with eight facilities ... 1949 by integrating a number of academic schools ...
(Date:12/15/2009)... be donated to the Lupus Foundation of America and ... Dec. 15 Julian Lennon, son of the ... their new digital single, "LUCY," to raise funds for ... 15, 2010, 100 percent of the proceeds from downloading ... Foundation of America (LFA), and the Saint Thomas, Lupus ...
(Date:12/15/2009)... YORK, Dec. 15 Vitech Systems Group, ... Relationship Management (CRM) software, announced today that it ... implementation for the Screen Actors Guild-Producers Pension & ... advanced customer service capabilities to SAG-PH call center ... system was installed using Vitech,s V3 Benefits Administration ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2
... disease care, study finds , , TUESDAY, Oct. 2 (HealthDay ... rates of chronic disease in the United States, with ... a new study finds. , It,s an expensive problem, ... and heart disease account for some $100 to $150 ...
... MIT Holding, Inc. (OTCBB: MITD - News), has signed ... to stop the spread of infectious diseases. Dr. ... and Director of the Biodefense and Infectious Disease Laboratory ... College of Public Health, Georgia Southern University, will oversee ...
... PA, October 2, 2007 The first significant genetic ... reported. PMDD is a very severe form of ... PMDD is heritable, affects 5-8% of women, and is ... irritability, marked depressed mood, anger, headaches, weight gain and ...
... /PRNewswire/-- Meretek Diagnostics, Inc. and,Otsuka America Pharmaceutical, Inc. ... the two companies. The merger forms a new ... America Pharmaceutical,Inc. OAPI was established in 1989 ... by Otsuka Pharmaceutical Co., Ltd. (OPC). Meretek Diagnostics,was ...
... Fibertec, a division of,Filtrona plc, developer of fiber-based ... celebrated the completion,of the recent expansion of its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ) The ... the size of,production floor space and an expanded ...
... TOWN, W.V., Oct. 2 /PRNewswire-FirstCall/-- ReBuilder Medical,Technologies, Inc. ... the,increasing demand for its products it has had ... in the past three weeks alone. (Logo: ... PhD, CEO of ReBuilder, stated, "We have been,marketing ...
Other Medicine News:Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger 2Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 2Health News:ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: